journal
MENU ▼
Read by QxMD icon Read
search

Neurodegenerative Disease Management

journal
https://www.readbyqxmd.com/read/29683408/palatability-and-oral-cavity-tolerability-of-thc-cbd-oromucosal-spray-and-possible-improvement-measures-in-multiple-sclerosis-patients-with-resistant-spasticity-a-pilot-study
#1
Giacomo Lus, Roberto Cantello, Maura Chiara Danni, Agusto Rini, Paola Sarchielli, Tiziana Tassinari, Elisabetta Signoriello
AIM: Complaints about Δ9 -tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex® ; GW Pharma Ltd, Sailsbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects. MATERIALS & METHODS: Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17)...
April 23, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29633651/age-disease-duration-influence-on-activities-of-daily-living-and-quality-of-life-after-levodopa-carbidopa-intestinal-gel-in-parkinson-s-disease
#2
Angelo Antonini, Weining Z Robieson, Lars Bergmann, Ashley Yegin, Werner Poewe
AIM: To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living. PATIENTS & METHODS: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of 'off' time and levodopa equivalent dose. Patients' data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG...
April 10, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29564954/the-role-of-extended-release-amantadine-for-the-treatment-of-dyskinesia-in-parkinson-s-disease-patients
#3
Elkurd T Mazen, Laxman B Bahroo, Rajesh Pahwa
Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia...
March 22, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29557715/treating-ms-without-continuous-immunosuppression-an-interview-with-luciano-rossetti
#4
Luciano Rossetti
Luciano Rossetti, MD, Executive Vice President, Global Head of R&D at Merck KGaA, Darmstadt, Germany speaks to Laura Dormer, Commissioning Editor Luciano Rossetti, MD, is Executive Vice President, Global Head of R&D at Merck KGaA, Darmstadt, Germany, and a member of the Healthcare Executive Committee. As Global Head of R&D, Rossetti leads the strategy for Merck KGaA, Darmstadt, Germany's discovery and development efforts in healthcare. He joined Merck KGaA in July 2014, and has since led the acceleration of several key programs through the pipeline and advanced the innovation of Merck KGaA's discovery teams into development...
March 20, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29517417/octagam-%C3%A2-for-chronic-inflammatory-demyelinating-polyneuropathy-results-from-three-observational-studies
#5
Stefan Wietek
AIM: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Data on patients with CIDP treated with octagam were analyzed to assess its safety and tolerability. RESULTS: Of 2314 patients included in the studies, 58 patients (mean age: 64.6 years) received octagam for CIDP, mean dose of which was 0...
March 8, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29412787/measurement-of-respiratory-function-decline-in-patients-with-duchenne-muscular-dystrophy-a-conjoint-analysis
#6
Elena Ripamonti, Grazia D'Angelo
AIM: In Duchenne muscular dystrophy (DMD), little attention has been paid to severity of respiratory function decline (RFD) based on disease progression. We performed a conjoint analysis among 123 Italian clinicians to generate a scale for RFD in DMD patients. METHODS: Before the interview, 11 attributes were selected by discussion among experts. Thirty-two 'patient profiles' were generated. Each physician assessed the severity of RFD for each profile. Each level/attribute was assigned an estimated usefulness to understand its impact on RFD...
February 7, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29384036/the-exciting-field-of-neuro-repair-in-multiple-sclerosis-an-interview-with-sarah-i-sheikh
#7
Sarah I Sheikh
Sarah Isabel Sheikh speaks to Laura Dormer, Commissioning Editor: Sarah I Sheikh, MD, MSc, MRCP, is a Senior Medical Director in Late Stage Clinical Development at Biogen. Her current focus is on developing therapies for multiple sclerosis/neuroinflammation, remyelination and neuro-repair. Prior to Biogen, Dr Sheikh was an attending in Neurology at Brigham and Women's Hospital. She completed her internship at Massachusetts General Hospital and residency in Neurology and Neuromuscular fellowship at Massachusetts General Hospital and Brigham and Women's Hospital...
January 31, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29400629/introducing-volume-8-of-neurodegenerative-disease-management
#8
Laura Dormer
Welcome to the eighth volume of Neurodegenerative Disease Management. At the start of a new volume, it is interesting to look back at which content proved most popular in 2017, and also to take a look forward to the content of this issue and beyond.
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29372815/understanding-important-issues-in-young-onset-dementia-care-the-perspective-of-healthcare-professionals
#9
John H Spreadbury, Christopher M Kipps
AIM: Psychosocial research on the lived experiences of young-onset dementia patients and caregivers has identified salient issues about their care, however, views on care from the perspective of young-onset dementia healthcare professionals is less well known. The aim of this study was to investigate and identify important issues in young-onset dementia care provision from a healthcare provider perspective. METHODS: The design was an exploratory qualitative interview study...
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29359625/vision-in-alzheimer-s-disease-a-focus-on-the-anterior-afferent-pathway
#10
Victoria S Pelak, William Hills
Visual dysfunction has long been recognized as a manifestation of Alzheimer's disease (AD), particularly in the form of visuospatial impairment during all stages of disease. However, investigations have revealed findings within the anterior (i.e., pregeniculate) afferent visual pathways that rely on retinal imaging and electrophysiologic methodologies for detection. Here we focus on the anterior afferent visual pathways in AD and the measures used for assessment, including optical coherence tomography, electrophysiology, color vision testing and threshold visual field perimetry...
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29316850/demographics-and-clinical-characteristics-of-primary-lateral-sclerosis-case-series-and-a-review-of-literature
#11
Ramnath Santosh Ramanathan, Sandeep Rana
AIM: Primary lateral sclerosis (PLS) is a form of motor neuron disease involving only upper motor neurons. In some patients presenting as PLS, the disease progresses to involve lower motor neurons and thereby converting to amyotrophic lateral sclerosis (ALS). However, pure forms of PLS do exist. Our aim was to study epidemiological and clinical characteristics of pure PLS patients treated at our neuromuscular clinic. METHODS: We retrospectively reviewed 15 patients from July 2011 to October 2014 with PLS treated at the neuromuscular disorder clinic at our hospital...
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29308710/medication-adherence-and-adverse-effect-profile-of-antiepileptic-drugs-in-nigerian-patients-with-epilepsy
#12
Joseph O Fadare, Taofiki A Sunmonu, Idowu A Bankole, Kehinde A Adekeye, Sani A Abubakar
AIM: Medication adherence remains a major challenge among patients with epilepsy (PWE) with the adverse effect profile of antiepileptic drugs (AEDs) as one of its main drivers. METHODS: This was a cross-sectional questionnaire-based study among PWE in selected Nigerian tertiary healthcare facilities using the Morisky Medication Adherence Scale and the Liverpool Adverse Effect Profile (LAEP). RESULTS: 126 PWE from four tertiary healthcare facilities were included in this study comprising of 59 (46...
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29301440/advancing-the-understanding-of-progression-in-multiple-sclerosis-an-interview-with-shibeshih-belachew
#13
Shibeshih Belachew
Shibeshih Belachew speaks to Laura Dormer, Commissioning Editor: Dr Shibeshih Belachew, MD, PhD, is a Senior Medical Director for Multiple Sclerosis (MS) Disease Area in Global Product Development Medical Affairs at Roche (Basel, Switzerland). Prior to joining Roche in January 2016, he was Director of MS Franchise and Head of Medical Director's office for Biogen Region Europe and Canada. Previously at Biogen he also served as a Director in Global Neurology for the natalizumab program in Cambridge (MA, USA)...
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29297249/stim-proteins-as-regulators-of-neuronal-store-operated-calcium-influx
#14
Elena Popugaeva, Ilya Bezprozvanny
No abstract text is available yet for this article.
February 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29319406/completed-suicide-in-an-autopsy-confirmed-case-of-early-onset-alzheimer-s-disease
#15
Jennifer Wiener Hartzell, Richard Geary, Kymberly Gyure, Venkata Ravi Chivukula, Marc W Haut
We report a case of a 57-year-old male with clinically diagnosed and autopsy-confirmed early onset Alzheimer's disease who completed suicide by gunshot wound to the chest. This case has several unique aspects that have not been discussed in previous case reports of completed suicide in Alzheimer's disease. In particular, our patient's death was highly planned with successful compensation for his cognitive deficits. After all firearms had been removed from the home as a safety precaution, he obtained a new weapon, hid it and left himself cues to find and use it...
January 10, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29185371/recent-advances-in-longitudinal-structural-neuroimaging-of-younger-onset-dementias
#16
Ramon Landin-Romero, Olivier Piguet
No abstract text is available yet for this article.
December 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29165027/patient-centered-decision-making-in-amyotrophic-lateral-sclerosis-where-are-we
#17
Anne Hogden, Ashley Crook
Developments in amyotrophic lateral sclerosis research and care delivery have created new arenas, and new dilemmas, for patients' decision making. This review explores three aspects of amyotrophic lateral sclerosis patient-centered care and decision making: patient-centered service delivery through the expanding multidisciplinary team; decision making for genetic testing and the implications of undergoing testing; and development of user-designed decision support tools to help patients and families make decisions as their choices become more complex...
December 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29165011/motor-imagery-of-walking-and-walking-while-talking-a-pilot-randomized-controlled-trial-protocol-for-older-adults
#18
Helena M Blumen, Joe Verghese
Over a third of community-residing elderly have clinical gait abnormalities, and gait impairment is associated with morbidity, mortality and dementia. Motor imagery - envisioning motor actions without actual execution - has been used to improve gait in Parkinson's disease and poststroke, but the efficacy of motor imagery in healthy elderly is unknown. This single-blind pilot randomized-controlled trial aims to establish feasibility and explore the efficacy of a 3-month, telephone-based motor imagery intervention - that involves imagined walking, imagined talking and imagined walking while talking for improving gait in 48 healthy elderly...
December 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29160146/dementia-risk-assessment-tools-an-update
#19
Eugene Yee Hing Tang, Louise Robinson, Blossom Christa Maree Stephan
No abstract text is available yet for this article.
December 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29160144/parkinson-s-disease-psychosis-presentation-diagnosis-and-management
#20
Ruth B Schneider, Julia Iourinets, Irene H Richard
Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions. PDP is associated with reduced function and quality of life. The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia...
December 2017: Neurodegenerative Disease Management
journal
journal
42631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"